Amendments to Mexico’s Federal Law for Protection of Industrial Property Inform More Flexible International IP Strategy for Biotech Companies
Key Takeaway: Amendments to Mexico’s Federal Law for Protection of Industrial Property align more with U.S. Patent and Trademark Office standards for restoring priority and application revival, increasing international patent...
Knobbe Martens, Dozens of Partners Receive Top Rankings in IP Law in Legal 500 USA Guide
IRVINE, Calif., June 11, 2026 – Knobbe Martens, a leading intellectual property law firm, is proud to share that the firm and three dozen lawyers received national and regional recognition...
Life Science Update | May 2026
AI Risks With the Patent Office: What Life Science Companies Should Be Asking Now Robert J. Hilton, Ph.D. & Justin Culbertson, Ph.D. AI tools are reshaping patent preparation and prosecution,...
Dozens of Knobbe Martens Partners Recognized in 2026 IAM Patent 1000 Guide
IRVINE, Calif., May 28, 2026 – Knobbe Martens, a leading intellectual property law firm, and its partners were once again recognized for excellence across patent law in the 2026 edition...
Life Science Update | April 2026
One Battle After Another: Broad Institute Wins at PTAB in CRISPR Dispute Eric Furman, Ph.D. & Alistair J. McIntyre Interference proceedings, though increasingly rare, are heavily evidence-based and determine which...
Knobbe Martens Named Life Sciences Prosecution Firm of the Year at Life Sciences Patent Network Awards
IRVINE, Calif., May 1, 2026 – Knobbe Martens is proud to share the firm received the “Life Sciences Prosecution Firm of the Year” award at the 2026 Life Sciences Patent...
Three Knobbe Martens Partners Named Los Angeles Times “Life Sciences Visionaries”
IRVINE, Calif., April 20, 2026 – Knobbe Martens is pleased to share that partners Salima Merani, Ph.D., Jason Jardine, and Kimberly Miller, Ph.D. have been recognized as “Life Sciences Visionaries”...
Well-Known Genus, Novel Method: A Post-Amgen Framework for Written Description & Enablement
Key Takeaways: Recent Federal Circuit decision draws a meaningful distinction between patents that claim a broad genus as the invention itself and those that claim a novel therapeutic method using...
Life Science Update | December 2025
Purdue Pharma’s $7.4 Billion Chapter 11 Plan Formally Approved Eric Furman, Ph.D. & Rhett D. Ramsey A federal bankruptcy court on November 18 formally approved Purdue’s $7.4 billion Chapter 11...
USPTO’s Automated Search Pilot: Through a Biotech Lens
In October 2025, the U.S. Patent and Trademark Office (USPTO) launched the “Artificial Intelligence Search Automated Pilot Program,” or ASAP!, an initiative to identify potential prior art using artificial intelligence...
Will the Bankruptcy of “Forever 21” Strengthen IP Rights?
For the second time since its founding in 1984, the fast-fashion movement leader, Forever 21, has filed for bankruptcy and is expected to close its over 350 U.S. locations and...
Rare Disease Therapies Gain Momentum With Regulatory Support and Continued Market Growth
The landscape for rare disease treatments appears to be evolving rapidly, thanks to a confluence of regulatory momentum and a booming market forecast. Statements from key federal figures in recent...
Knobbe Martens, Dozens of Firm Partners Recognized in Legal 500 U.S.A. Guide
Firm again receives standout rankings in multiple practice areas, including prosecution, trademarks, licensing, and litigation IRVINE, Calif., June 17, 2025 – Knobbe Martens is proud to announce that the firm...
Knobbe Martens Celebrated as “Excellent IP Firm,” Dozens of Partners Recognized for Top-Tier Patent Work in IAM Patent 1000 Guide
IRVINE, Calif., June 3, 2025 – Knobbe Martens is pleased to share that the firm and two dozen of its partners from offices throughout the country have been featured in...
Suspension of the Climate Change Mitigation Pilot Program: What Happens Now?
Effective January 28, 2025, the new administration suspended the Climate Change Mitigation Pilot Program (CCMPP) at the United States Patent and Trademark Office (USPTO).[1] The USPTO had instituted this program...
Heading Towards an Optimistic Initial Public Offerings (IPOs) Resurgence in 2025?
On January 16th, 2025, GT Medical Technologies, announced that it has raised $37 million in Series D financing round. The financing round was led by Evidity Health Capital and joined...
End of an Era: The After Final Consideration Pilot Program 2.0 Concludes
The sun is officially setting on the United States Patent and Trademark Office’s (USPTO) After Final Consideration Pilot Program 2.0 (AFCP 2.0)[1]. This program, which has been instrumental in facilitating...
Settlements Don’t Close the Door: Antitrust Claims Follow IPR Challenges in Life Sciences
In the ongoing case of Carefirst of Maryland Inc. v. Johnson & Johnson[1], the plaintiffs successfully overcame a motion to dismiss. At the heart of the case is J&J’s legal...
FDA Approves Colony Stimulating Factor-1 Receptor (Csf-1R) Blocking Antibody for Treatment of Chronic Graft-Versus-Host Disease (Cgvhd)
On August 14, 2024, the U.S. Food and Drug Administration (FDA) approved a colony stimulating factor-1 receptor (CSF-1R)-blocking antibody, NIKTIMVO (axatilimab-csfr) developed by Incyte Corporation (and in-licensed from Syndax Pharmaceuticals), for treatment of chronic graft-versus-host disease (cGvHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.
Understanding the Dangers of Counterfeit Drugs Through the Lens of Fake Ozempic
The June 2024 issue of Vanity Fair included the provocative headline: “Why Counterfeit Ozempic Is a Global-Growth Industry." Novo Nordisk’s patented drug Ozempic® (semaglutide injection) was first approved by the FDA in 2017 for the treatment of type 2 diabetes. A few years later, clinical trials demonstrated that Ozempic® could also be used for weight loss in individuals without diabetes who had previously struggled to lose weight. News of the “miraculous weight loss” achieved with Ozempic® (and its sister drug Wegovy®) led to widespread demand for the drug and global shortages.
Knobbe Martens’ Across-the-Board Strength in Patent Work Recognized in IAM 2024 Patent 1000 Guide
IRVINE, Calif., June 21, 2024 – Knobbe Martens is proud to announce that multiple practices across the firm and two dozen partners were recognized nationally and regionally for outstanding work...
